Joe Chan

Mr. Joe Chan

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2022 in Blood
Verified
Journal Article
Open access
PDF file
UVUmeshkumar Vekariya
Umeshkumar Vekariya
MTMonika Toma
Monika Toma
MNMargaret Nieborowska-Skorska
Margaret Nieborowska-Skorska
BLBac Viet Le
Bac Viet Le
MCMarie-Christine Caron
Marie-Christine Caron
TSTomasz Skorski
Tomasz Skorski
Leukemia cells accumulate DNA damage but altered DNA repair mechanisms protect them from apoptosis. We showed here that formaldehyde generated by serine/one-carbon cycle metabolism contributed to accumulation of toxic DNA-protein crosslinks (DPCs) in leukemia cells, especially in driver clones harboring oncogenic tyrosine kinases [OTKs: FLT3(ITD), JAK2(V617F), BCR/ABL1]. To counteract this effect, OTKs enhanced the expression of DNA polymerase theta (POLq) by ERK1/2 serine/threonine kinase-dependent inhibition of c-CBL E3 ligase-mediated ubiquitination of POLq and its proteasomal degradation. Overexpression of POLq in OTK-positive cells resulted in efficient repair of DPC-containing DNA double-strand breaks (DSBs) by POLq-mediated end-joining (TMEJ). Transforming activity of OTKs and other leukemia-inducing oncogenes, especially of those causing inhibition of BRCA1/2 -mediated homologous recombination (HR) with and without concomitant inhibition of DNA-PK -dependent non-homologous end-joining (D-NHEJ), was abrogated in Polq-/- murine bone marrow cells. Genetic and pharmacological targeting of POLq polymerase and helicase activities revealed that both activities are promising targets in leukemia cells. Moreover, OTK inhibitor or DPC-inducing drug etoposide enhanced anti-leukemia effect of POLq inhibitor (POLqi) in vitro and in vivo. In conclusion, we demonstrated that POLq plays an essential role in protecting leukemia cells from metabolically induced toxic DNA lesions triggered by formaldehyde and that it can be targeted to achieve therapeutic effect.

25 August 2022 in Cancer Prevention Research
Verified
Journal Article
Open access
PDF file
JGJayashri Ghosh
Jayashri Ghosh
BSBryant M. Schultz
Bryant M. Schultz
JCJoe Chan
Joe Chan
CWClaudia Wultsch
Claudia Wultsch
RSRajveer Singh
Rajveer Singh
CSCarmen Sapienza
Carmen Sapienza
Nongenetic predisposition to colorectal cancer continues to be difficult to measure precisely, hampering efforts in targeted prevention and screening. Epigenetic changes in the normal mucosa of patients with colorectal cancer can serve as a tool in predicting colorectal cancer outcomes. We identified epigenetic changes affecting the normal mucosa of patients with colorectal cancer. DNA methylation profiling on normal colon mucosa from 77 patients with colorectal cancer and 68 controls identified a distinct subgroup of normally-appearing mucosa with markedly disrupted DNA methylation at a large number of CpGs, termed as “Outlier Methylation Phenotype” (OMP) and are present in 15 of 77 patients with cancer versus 0 of 68 controls (P < 0.001). Similar findings were also seen in publicly available datasets. Comparison of normal colon mucosa transcription profiles of patients with OMP cancer with those of patients with non-OMP cancer indicates genes whose promoters are hypermethylated in the OMP patients are also transcriptionally downregulated, and that many of the genes most affected are involved in interactions between epithelial cells, the mucus layer, and the microbiome. Analysis of 16S rRNA profiles suggests that normal colon mucosa of OMPs are enriched in bacterial genera associated with colorectal cancer risk, advanced tumor stage, chronic intestinal inflammation, malignant transformation, nosocomial infections, and KRAS mutations. In conclusion, our study identifies an epigenetically distinct OMP group in the normal mucosa of patients with colorectal cancer that is characterized by a disrupted methylome, altered gene expression, and microbial dysbiosis. Prospective studies are needed to determine whether OMP could serve as a biomarker for an elevated epigenetic risk for colorectal cancer development. Prevention Relevance: Our study identifies an epigenetically distinct OMP group in the normal mucosa of patients with colorectal cancer that is characterized by a disrupted methylome, altered gene expression, and microbial dysbiosis. Identification of OMPs in healthy controls and patients with colorectal cancer will lead to prevention and better prognosis, respectively.

7 May 2026 in Nature Communications
Verified
Journal Article
Open access
ZXZhuoran Xu
Zhuoran Xu
Hui-Qi QuHui-Qi Qu
Hui-Qi Qu
JCJoe Chan
Joe Chan
SMShizhuo Mu
Shizhuo Mu
CKCharlly Kao
Charlly Kao
KWKai Wang
Kai Wang
Recent advances in long-read single-cell transcriptome sequencing (lr-scRNA-Seq) enable full-length isoform profiling at single-cell resolution. We present SCOTCH (Single-Cell Omics for Transcriptome CHaracterization), an end-to-end, platform-independent pipeline for isoform characterization from lr-scRNA-Seq data, supporting Nanopore and PacBio sequencing as well as 10X Genomics and Parse Biosciences protocols. SCOTCH models isoforms as combinations of non-overlapping sub-exons and applies dynamic thresholding for robust isoform assignment while efficiently address ambiguous mapping issues. By refining sub-exon boundaries through integration of read coverage with existing annotations and applying an iterative clustering strategy to reconstruct novel transcripts, SCOTCH reliably recovers more true novel isoforms than existing splice-graph-based methods, with poly(A)-aware filtering further reducing false-positive structures. Extensive simulations demonstrate improved quantification of known isoforms and enhanced reconstruction of novel isoforms. Analyses of human blood and cerebral organoid datasets across multiple platforms further confirm SCOTCH's ability to resolve cell-type-specific transcriptome profiles and uncover experimentally supported novel isoforms.

1 January 2026 in JCO Precision Oncology
Verified
Journal Article
Open access
WBWynn E. Bastianelli
Wynn E. Bastianelli
JWJinhua Wu
Jinhua Wu
MAMian Umair Ahsan
Mian Umair Ahsan
ASAva M. Szepessy
Ava M. Szepessy
JSJeffery Schubert
Jeffery Schubert
MLMarilyn M. Li
Marilyn M. Li

3 April 2023
Verified
Other
Open access
JGJayashri Ghosh
Jayashri Ghosh
BSBryant M. Schultz
Bryant M. Schultz
JCJoe Chan
Joe Chan
CWClaudia Wultsch
Claudia Wultsch
RSRajveer Singh
Rajveer Singh
CSCarmen Sapienza
Carmen Sapienza
Supplementary Figure from Epigenome-Wide Study Identifies Epigenetic Outliers in Normal Mucosa of Patients with Colorectal Cancer

3 April 2023
Verified
Other
Open access
JGJayashri Ghosh
Jayashri Ghosh
BSBryant M. Schultz
Bryant M. Schultz
JCJoe Chan
Joe Chan
CWClaudia Wultsch
Claudia Wultsch
RSRajveer Singh
Rajveer Singh
CSCarmen Sapienza
Carmen Sapienza
Supplementary Figure from Epigenome-Wide Study Identifies Epigenetic Outliers in Normal Mucosa of Patients with Colorectal Cancer